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ABSTRACT 
Background: When phenytoin is prescribed for administration via nasogas- 
tric tube, immediate-release OR) phenytoin tablets are crushed before use and 
extended-release (ER) phenytoin capsules are opened and only the granules are 
used. However, it is unknown whether the same dose of these 2 different formu- 
lations will result in the same steady-state s rum phenytoin concentration. 
Objective: The aim of this study was to determine whether ER phenytoin 
capsules can be used interchangeably with IR phenytoin tablets for prophy- 
laxis of posttraumatic seizures. 
Methods: Inpatients at the neurosurgical ward at Prasat Neurological 
Institute, Bangkok, Thailand, between October 2004 and October 2005 were 
enrolled in the study. All patients were initially prescribed IR phenytoin tablets 
300 mg/d as a maintenance dose for prophylaxis of posttraumatic seizures. 
The serum phenytoin concentration was measured after >5 days of treatment 
with IR phenytoin tablets 300 mg/d (two 50-mg tablets every 8 hours) that had 
been crushed before being administered concomitantly with a blenderized iet 
through the nasogastric tube. Without a washout period, the dosage form was 
changed to ER phenytoin capsules (three 100-mg capsules QD). The capsules 
were opened and the contents were administered concomitantly with the blen- 
derized diet through the nasogastric tube for >5 days. The serum phenytoin 
concentration was again determined. The patients were closely monitored for 
seizures and adverse vents (AEs). 
Results: Thirty-three patients enrolled in the study and 17 (10 women, 7 men; 
mean [SD] age, 62.94 [15.94] years [range, 18-89 years]) completed the study. The 
mean (SD) serum phenytoin concentrations after administration of phenytoin 
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tablets and capsules were 6.03 (5.92) 1Jg/mL and 3.80 (2.71) 1Jg/mL, respectively 
(P = 0.019). The mean serum phenytoin concentrations, adjusted for low serum 
albumin concentrations after administration f tablets and capsules, were calcu- 
lated and reported to be 10.33 (11.60) 1Jg/mL and 6.28 (4.76) 1Jg/mL, respectively 
(P = 0.035). The maximum phenytoin metabolic rate (Vma×) (assuming the sub- 
strate concentration at which the rate of metabolism is one half Vma × = 4 mg/L) after 
the administration f phenytoin tablets and capsules was 8.37 (2.42) mg/kg • d -1 
and 10.38 (6.48) mg/kg • d -1, respectively. These values were not significantly dif- 
ferent. All patients were seizure-free and no AEs were observed. 
Conclusion: The steady-state s rum phenytoin concentration was signifi- 
cantly lower with ER phenytoin capsules 300 mg/d than IR phenytoin tablets 
300 mg/d administered via nasogastric feeding tube concomitantly adminis- 
tered with a blenderized iet in these neurosurgical patients. (Curt Ther Res 
Clin Exp. 2007;68:325-337) Copyright © 2007 Excerpta Medica, Inc. 
Key words: phenytoin, nasogastric tube feeding, extended-release capsule, 
immediate-release tablet. 
INTRODUCTION 
Epilepsy is one of the most common serious central nervous ystem disorders, 
affecting 50 million people worldwide. 1 It may cause persistent deformity (eg, 
neuronal destruction, brain damage, cognitive decline), decrease quality of 
life, and necessitate expensive treatment. In Thailand, the prevalence of epi- 
lepsy is 29.2/1000 persons and the prevalence of active epilepsy is 5.9/1000 per- 
sons. 2 Although there is increasing interest in the use of new antiepileptic 
drugs (AEDs) (eg, lamotrigine, gabapentin, topiramate, and vigabatrin) for the 
management of seizure disorders in adult and elderly patients, the majority 
of these patients are still treated with traditional AEDs (eg, phenobarbital, 
carbamazepine, valproic acid, and phenytoin). In Thailand, phenytoin is a com- 
monly used AED for adults and elderly patients because it is effective for most 
common seizure types. 2 Phenytoin is inexpensive, causes minimal sedation, 
can be given once daily, and is available in oral and parenteral formulations. 3 
Although phenytoin is available in many formulations, extended-release (ER) 
phenytoin capsules have become popular because they are associated with good 
compliance. ER phenytoin capsules are available in all hospitals of Thailand, 
while immediate-release (IR) phenytoin tablets are only available in some hospi- 
tals. Therefore, patients who are prescribed phenytoin while they are receiving 
enteral tube feeding might be administered either IR phenytoin tablets or ER 
phenytoin capsules through the nasogastric tube. Because the whole tablet or 
capsule cannot be fed directly through the nasogastric tube, the tablet must be 
crushed or the capsules need to be opened so that only the granules are used. 
In 1982, Bauer 4reported low serum concentrations of phenytoin in 20 neu- 
rosurgical patients receiving 300 mg of phenytoin suspension via nasogastric 
tube while they were receiving continuous nasogastric tube feedings. When the 
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feedings were discontinued, the average phenytoin concentration i creased 
from 2.59 1Jg/mL to 10.22 1Jg/mL within 7 days. Subsequently, several studies 5-8 
supported this interaction, while others 9-u did not. The exact mechanism of 
interaction is unknown. Some studies uggested that a physical incompatibility 
between phenytoin and certain components of enteral feeding formulas (eg, 
protein hydrolysate) resulted in binding of phenytoin particles and a subse- 
quent decrease in bioavailability. 12-14 One study 15 suggested that binding of 
phenytoin to the tube lumen was the mechanism underlying this effect, while 
others 14,16,17 proposed that the interaction was pH-related. 
There is no indication for using either phenytoin tablets or phenytoin cap- 
sules in patients receiving enteral tube feeding; however, when phenytoin is 
prescribed for these patients, it is a common practice to dispense the IR tablet 
form, because crushing an IR dosage form is generally not prohibited as a 
method of administration. Where the tablet is not available, ER phenytoin cap- 
sules are used. Because ER dosage forms are generally not modified, the ques- 
tion emerges as to whether discarding the capsule and using only the granules 
will affect the bioavailability and, in turn, the clinical outcome. Phenytoin 
plasma concentration of 10 to 20 mg/L is generally accepted as therapeutic. 
Plasma concentrations in the range of 5 to 10 mg/L can be therapeutic for some 
patients, but concentrations <5 mg/L are not likely to be effective. 
The aim of this study was to determine whether ER phenytoin capsules 
(using only the granules) can be used interchangeably with IR phenytoin tab- 
lets (which have been crushed) by comparing steady-state s rum phenytoin 
concentrations after administration through an enteral feeding tube. 
PATIENTS AND METHODS 
Patients 
This was an open-label, crossover clinical trial comparing steady-state 
serum phenytoin concentration (Css) after administration of phenytoin acid 
IR 50-mg tablets* and phenytoin sodium ER 100-mg capsulest (equivalent to 
92 mg of phenytoin acid) through anasogastric tube. Participants were patients 
at Prasat Neurological Institute (Bangkok, Thailand). The study design was 
approved by the Human Research Committee of Prasat Neurological Institute. 
Written informed consent was obtained from the patient or his/her legal 
guardian prior to entering the study. The study was conducted in accordance 
with the principles of the Declaration of Helsinki 18 and the Guideline for Good 
Clinical Practice. 19 
Patients aged >18 years who were to receive nutrition via a nasogastric feed- 
ing tube and who were prescribed 300 mg of phenytoin monotherapy asa main- 
tenance dose for posttraumatic seizure control were eligible for the study. 
*Trademark: Dilantin Infatabs ® (Parke-Davis, New York, New York). 
tTrademark: Dilantin Kapseals ® (Parke-Davis). 
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Patients were excluded from the study if they were allergic to phenytoin, 
their dose of phenytoin had to be changed, another antiepileptic drug had to 
be added, any drug that might affect phenytoin pharmacokinetics had to be 
added, the nasogastric feeding tube was removed, or if they were discharged 
from the hospital or died before completion of the study. 
Study Design 
The study was started with the administration of phenytoin tablets, 
300 mg/d (two 50-mg tablets every 8 hours). The tablets were crushed, mixed 
into -200 mL of blenderized iet (Prasat Neurological Institute formula com- 
posed of pork liver, pumpkin, banana or papaya, egg, sugar, vegetable oil, and 
water), and administered via the nasogastric tube (Curity ®, Kendall-Gammatron 
Inc., Nakhonpathom, Thailand), followed by -50 mL of water. The same dosage 
form, administration time, and administration process were continued for >5 days 
to ensure steady-state conditions. One blood sample was then obtained from 
the vein at the forearm <1 hour before the morning dose, and the serum pheny- 
toin concentration was determined. 
The dosage formulation was then changed to phenytoin capsules in all 
patients, 300 mg/d (three 100-mg capsules once daily). There was no washout 
period. The capsules were opened and the contents were mixed into -200 mL 
of blenderized iet and administered via the nasogastric tube, followed by 
-50 mL of water. This process was again continued for >5 days, when 1 blood 
sample was collected from the forearm <1 hour before the morning dose, and 
the serum phenytoin concentration was determined. 
The incidences of seizures and minor and serious adverse vents (AEs) were 
observed and recorded. 
Blood Sample Collection 
For each patient, a 5-mL blood sample was drawn from the vein at the fore- 
arm <1 hour before the administration of the morning dose of phenytoin on 
day 5 to obtain the Cmh ~. The sample was centrifuged at 5000 rpm for 5 minutes, 
and the serum was separated. Immediate assay was preferred; if the assay 
could not be completed within 8 hours, the serum was stored at 2°C to 8°C until 
the assay could be completed, which was usually within 24 hours. 
The phenytoin concentration i serum samples was determined using a 
turbid metric inhibition immunoassay method with an automated analyzer 
(Synchron CX ® Systems, Beckman Coulter Inc., Fullerton, California). 
Statistical Analysis 
Since the sample size is small, <20, the test statistic Z cannot always be 
assumed to be normally distributed. Both a parametric method (comparison of 
the means using paired t tests) and a nonparametric method (Wilcoxon signed- 
rank test under the null hypothesis that the median difference is equal to 0) 
were performed by SPSS version 11.5 software (SPSS Inc., Chicago, Illinois). 
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Sample Size Estimation 
Sample size was est imated according to the formula2°: 
N = S2(Zc~ + Z[3)2/D2 ,
where S was defined as standard eviation, Z~ and Z6 were defined as the values 
that cut off the areas of c¢ and 13 in the upper and lower tails of the standard nor- 
mal distribution, and D was defined as the difference needed to detect a signifi- 
cant change in clinical outcomes (set to >1 1Jg/mL for the purpose of this study). 
Bauer 4 reported the mean (SD) serum phenytoin concentrat ion i 10 neu- 
rosurgical patients to be 2.59 (0.96) 1Jg/mL when a phenytoin suspension of 
300 mg/d was concomitant ly administered with continuous nasogastric feed- 
ing. Another 10 neurosurgical patients in that study receiving phenytoin sus- 
pension without concurrent  nasogastric tube feeding had a mean (SD) serum 
phenytoin concentrat ion of 2.72 (1.09) 1Jg/mL (the SDs from Bauer's study were 
used to estimate the sample size because the characterist ics of the patients 
and the dosage of phenytoin used were similar to those of the present study), 
the S 2 was calculated as follows: 
S 2 = S12 + S22/2 = (0.96) 2 + (1.09)2/2 = 1.05 
c¢ = 0.05 (2-sided); Z J2  = 1.96 
13 = 0.2 (power = 1-13 = 0.8); Z6 = 0.84. 
The difference detected (D) that might cause some significant changes in 
clinical outcome was set to be _>1 1Jg/mL; therefore, 
N = 1.05 (1.96 + 0.84)  2 = 8.23. 
Because the SDs of the Cs~ from tablet and capsule dosage forms were 
expected to be higher than those of the suspension dosage form used by Bauer, 
the sample size required was doubled and was determined to be >17 patients. 
Pharmacokinetic Parameter Calculation 
Phenytoin is -90% bound to serum albumin, and it is the pharmacological ly 
active unbound drug that is in equilibrium with the receptor site. Therefore, to 
correct  for patients who have hypoalbuminemia (serum albumin concentrat ion 
lower than the normal value of 4.4 g/dL), the normal binding serum phenytoin 
concentrat ion (eND) should be calculated using the following equation21: 
CNB = Cobs/0.9(Alb/4.4 ) + 0.1, 
where COb s is the measured serum phenytoin concentrat ion and Alb is the 
serum albumin concentration. 
The rate of phenytoin metabolism approaches its maximum at therapeutic 
concentrat ions and thus is descr ibed as capacity-limited, which results in 
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clearance values that decrease with increasing plasma concentrations. The 
maximum metabolic rate of phenytoin (Vmax) can be calculated from the for- 
mula that is derived from the Michaelis-Menten equation 21 as follows: 
Vmax/F = (S)(dose/~)(K m + C~)/C~s, 
where K,,,, the Michaelis-Menten constant, is the substrate concentration at 
which the rate of metabolism is half of Vma x (here, assumed to be 4 mg/L [popu- 
lation average]), F is the phenytoin bioavailability of the study dosage form, 
and Cs~ = CNB in this study. 
RESULTS 
Inpatient charts at the neurosurgical wards of Prasat Neurological Institute 
were screened from October 2004 to October 2005. Thirty-three patients who 
met the inclusion criteria were recruited. Four patients refused to enroll in 
the study and, after the initiation of the study, 3 patients discontinued the 
nasogastric feeding tube because they could take food by mouth, 4 patients 
were discharged from the hospital due to clinical improvement, 3 patients 
died, and 2 patients were excluded because the dosage of phenytoin had to 
be changed from 300 mg/d, leaving 17 patients to complete the study (10 wom- 
en, 7 men; mean [SD] age, 62.94 [15.94] years [range, 18-89 years]; mean [SD] 
weight, 61.18 [11.18] kg [range, 45-85 kg]; mean [SD] height, 160.88 [6.07] cm 
[range, 154-176 cm]). 
Baseline patient demographic haracteristics and laboratory findings are 
provided in Table I. Three (17.6%) patients had a history of smoking and 
5 (29.4%) had a history of alcohol abuse, although all of them had stopped 
smoking and consuming alcohol before entering the study. Of the patients who 
completed the study, 14 (82.4%) were admitted for cerebrovascular disease, 
2 (11.8%) had a brain tumor, and 1 (5.9%) had a head injury. Some patients 
had concomitant diseases, such as hypertension (9 [52.9%] patients), diabetes 
mellitus (1 [5.9%]), osteoarthritis (1 [5.9%]), and Parkinson's disease (1 [5.9%]). 
Approximately half of the patients showed abnormal liver function values 
(which might affect the elimination process of phenytoin and in turn affect 
serum phenytoin concentration), but all showed normal renal function values. 
Serum Phenytoin Concentration 
After _>5 days of treatment with phenytoin tablets, 300 mg/d to ensure steady- 
state condition, mean (SD) serum phenytoin Css was 6.03 (5.92) 1Jg/mL (median, 
4.60 1Jg/mL; range, 1.2-26.6 1Jg/mL). Mean (SD) serum albumin concentration 
was 2.51 (0.49) g/dL (median, 2.40 g/dL; range, 1.8-3.7 g/dL). Nearly all serum 
albumin concentrations (except for one) were lower than the normal range (3.5- 
5.0 gm/dL). Serum phenytoin CNB was  10.33 (11.60) 1Jg/mL (median, 6.99 1Jg/mL; 
range, 2.10-52.25 1Jg/mL) (Table II). 
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Table I. Baseline demographic characteristics and laboratory  f indings in neurosurgi- 
cal inpatients (N = 17). 
Age, Weight, AST, ALT, ALP, BUN, SCr, 
Patient Sex y kg mg/clL* mg/clL* mg/dLt mg/dL$ mg/dL§ 
1 M 68 65 23 16 81 17 1.1 
2 M 68 65 58 74 322 27 1.1 
3 M 67 75 39 48 86 12 0.8 
4 M 74 68 36 43 82 15 1.0 
5 M 39 70 29 32 111 10 0.9 
6 M 66 70 77 71 122 23 0.9 
7 F 89 45 22 16 95 20 1.1 
8 F 54 70 178 198 505 13 0.5 
9 F 71 67 17 23 100 28 1.2 
10 F 59 55 133 179 463 12 0.6 
11 F 18 50 66 57 102 6 0.7 
12 F 65 52 52 166 136 18 1.1 
13 F 79 48 75 59 261 12 0.8 
14 F 66 46 37 38 84 7 0.6 
15 F 53 53 28 28 111 18 0.8 
16 F 63 56 40 41 94 6 0.6 
17 M 71 85 97 217 148 15 0.9 
AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase; 
BUN = blood urea nitrogen; SCr = serum creatinine; M = male; F = female. 
*Normal range: 5 to 40 mg/dL. 
tNormal range: 35 to 125 mg/dL. 
~Normal range: 8 to 25 mg/dL. 
§Normal range: 0.6 to 1.6 mg/dL. 
After >5 days of treatment with phenytoin capsules, 300 mg/d, mean (SD) 
serum phenytoin Css was 3.80 (2.70) pg/mL (median, 3.00 pg/mL; range, 0.4- 
9.1 pg/mL). Serum albumin concentration was 2.45 (0.40) g/dL (median, 
2.60 g/dL; range, 1.8-3.2 g/dL). Serum phenytoin CNB was 6.28 (4.76) pg/mL, 
(median, 4.75 IJg/mL; range, 0.85-17.86 IJg/mL) (Table II). 
As shown in Table III, tablet and capsule Cs~ and CNB were significantly differ- 
ent at c¢ = 0.05 (2-sided) based on nonparametric method (P = 0.019 and 0.035, 
Wilcoxon signed rank test). However, tablet and capsule C~ and CNB were not 
significantly different at c¢ = 0.05 (2-sided) based on parametric method (P = 
0.054 and 0.075, paired ttest). Because of 1 patient with outlier values, the mean 
differences were again determined with parametric method without he data of 
that patient for both C~s (P = 0.028) and CNB (e = 0.051). 
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Table II. Serum phenytoin concentration and serum albumin concentration in neu- 
rosurgical patients. 
Tablet Formulation Capsule Formulation 
Patient 
Serum Albumin Serum Albumin 
Phenytoin Css , Concentration, C. B, Phenytoin Cs~, Concentration, C. B, 
I~g/mL g/dL I~gTr~L I~g/mL g/dL I~gTr~L 
1 5.1 3.7 5.95 4.3 2.6 6.81 
2 2.9 2.0 5.70 1.5 2.0 2.95 
3 26.6 2.0 52.25 9.1 2.0 17.86 
4 2.6 2.3 4.56 2.3 2.7 3.53 
5 3.5 3.1 4.77 5.7 2.9 8.22 
6 6.2 1.9 12.69 1.7 1.9 3.48 
7 4.7 2.8 6.99 6.7 2.2 12.18 
8 3.2 3.0 4.48 3.0 2.6 4.75 
9 4.0 2.3 7.01 2.5 3.2 3.31 
10 1.2 2.3 2.10 0.4 1.8 0.85 
11 6.0 2.7 9.20 6.1 2.7 9.35 
12 3.3 2.7 5.06 1.7 2.4 2.88 
13 7.0 2.4 11.85 4.9 2.7 7.51 
14 8.0 2.8 11.89 3.2 2.8 4.76 
15 12.1 2.7 18.55 8.9 2.6 14.09 
16 4.6 1.8 9.83 0.5 2.0 0.98 
17 1.5 2.2 2.73 2.1 2.6 3.32 
Mean (SD) 6.03 2.51 10.33 3.80 2.45 6.28 
(5.92) (0.49) (11.60) (2.70) (0.40) (4.76) 
Mean (SD)* 4.74 2.54 7.71 3.47 2.48 5.56 
(2.72) (0.49) (4.35) (2.41) (O.4O) (3.83) 
Median 4.60 2.40 6.99 3.00 2.60 4.75 
Css = steady-state serum phenytoin concentration; CNB = Css adjusted for a low serum albumin 
concentration. 
*Data for 1 outlier (patient 3) were excluded from the calculation. 
Clinical Outcomes 
None of the patients howed signs of seizures or minor or serious AEs asso- 
ciated with phenytoin use during the study period and none were reported by 
any patient. 
Michae l i s -Menten  Parameters  
Vmax/F (where F is a bioavailability factor; the percentage or fraction of the 
administered ose that reaches the systemic circulation) of each patient, as- 
suming K m = 4 mg/L, is shown in Table IV. Mean Vmax/F calculated from tablet 
Css was 501.32 (137.02) mg/d (median, 471.76 mg/d) or 8.37 (2.42) mg/kg • d -1 
(median, 8.11 mg/kg • d-l). Mean Vmax/F calculated from capsule Cs~ was 
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Table III. Comparison of the serum phenytoin steady-state concentration (Css) after 
administration of phenytoin capsules and tablets. 
P 
Serum Phenytoin 
Wilcoxon 
Paired t Test Signed-Rank Test 
Tablet Css versus capsule Cs~ 
All patients 0.054 
Without the outlier 0.028 
Tablet CNB versus capsule CNB 
All patients 0.075 
Without the outlier 0.051 
0.019 
0.035 
CNB = Css adjusted for a low serum albumin concentration. 
Table IV. Maximum phenytoin metabolic rate (Vmax) of individual patients, assuming 
K m = 4 mg/L. 
Tablet Vmax/F , Tablet Vmax/F , Capsule Vm~x/F , Capsule Vm~x/F , 
Patient mg/d mg/kg • d -1 mg/d mg/kg • d -1 
1 501.60 7.72 438.22 6.74 
2 510.66 7.86 650.69 10.01 
3 322.97 4.31 337.76 4.50 
4 563.29 8.28 589.09 8.66 
5 551.69 7.88 410.26 5.86 
6 394.57 5.64 593.33 8.48 
7 471.76 10.48 366.63 8.15 
8 567.61 8.11 508.51 7.26 
9 471.14 7.03 609.21 9.09 
10 870.45 15.83 1568.18 28.51 
11 430.45 8.61 394.05 7.88 
12 537.19 10.33 659.74 12.69 
13 401.30 8.36 422.96 8.81 
14 400.91 8.72 508.09 11.05 
15 364.69 6.88 354.37 6.69 
16 422.13 7.54 1400.07 25.00 
17 740.00 8.71 608.16 7.15 
Mean (SD) 501.32 (137.02) 8.37 (2.42) 612.90 (346.18) 10.38 (6.48) 
Median 471.76 8.11 508.51 8.48 
K m = Michaelis-Menten constant, the concentration of the substrate at which half the Vma x is 
achieved (when velocities are measured under initial rate and steady-state conditions); F = phenytoin 
bioavailability after the administration. 
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612.90 (346.18) mg/d (median, 508.51 mg/d) or 10.38 (6.48) mg/kg • d -1 (median, 
8.48 mg/kg • d-l). Neither the comparison of Vmax/F mg/d or Vmax/F mg/kg • d -1 
after administration of phenytoin tablets and capsules showed statistically 
significant differences at the 95% CI (Table V). 
DISCUSSION 
Serum phenytoin concentrations varied greatly among the patients after treat- 
ment with phenytoin tablets and also after treatment with phenytoin capsules 
via nasogastric tube. Phenytoin tablets and capsules require different meth- 
ods of preparation. In our study, the tablets were crushed and suspended in 
a blenderized iet before administration. Granule size depended on which 
investigator crushed the tablets, possibly resulting in variation in phenytoin 
bioavailability. Phenytoin capsules are more convenient to use, because they 
do not required crushing before administration. However, the granules were 
smaller and more bulky (lighter and higher in volume). Some granules tuck to 
the feeding tube and required additional water to flush them down, which also 
might have resulted in variation in bioavailability. 
All patients enrolled received a blenderized diet (Prasat Neurological 
Institute formula) through a nasogastric tube. Other studies, 12,15 which used 
commercial enteral feeding formulas, reported that the hydrolyzed protein or 
isolated protein in these formulas caused a decrease in serum phenytoin con- 
centration. Previous tudies found that coadministration f the drug with food 
caused the serum phenytoin concentration to be lower than with interrupted 
feeding, in which feeding was stopped for 2 hours before and 2 hours after pheny- 
toin was administered. 4,5 In our study, many patients administered with pheny- 
toin tablets or capsules via nasogastric tube had serum phenytoin concentra- 
tions that were lower than the proposed therapeutic range (10-20 pg/mL in 
general, 5-20 pg/mL in some patients). This might have been caused by the 
Table V. Comparison of the max imum phenyto in  metabol ic  rate (Vmax) obta ined 
after administrat ion of phenyto in  tablets and phenyto in  capsules, assuming 
K m = 4 mg/L. 
Wilcoxon Signed-Rank 
Vmax/F Paired t Test Test 
Tablet versus capsule, mg/d 0.139 0.246 
Tablet versus capsule, mg/kg • d -1 0.133 0.193 
K m = Michaelis-Menten constant, the concentration of the substrate at which half the Vma x is 
achieved (when velocities are measured under initial rate and steady-state conditions); F = phenytoin 
bioavailability after administration. 
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interaction of phenytoin with the enteral feeding formula (which contains intact 
protein) when the drug was coadministered with the diet. 
The main reason the serum phenytoin concentration obtained with capsules 
was significantly lower than that obtained with tablets might have been due to 
the difference in salt forms between the 2 dosing forms. The tablets contained 
phenytoin in free acid form, while the capsules contained phenytoin in sodium 
salt form. When a salt form of a drug is administered, the fraction of the total 
molecular weight hat is the active moiety should be considered. 21For pheny- 
toin sodium, 92% of the administered ose is active drug. Thus 300 mg of 
phenytoin sodium has 276 mg of phenytoin and 24 mg of sodium. Because 
metabolism of phenytoin is capacity-limited, resulting in nonlinear pharma- 
cokinetics, a small increase in the dosage could result in a disproportion- 
ately high increase in serum drug concentration. The dosage used in this 
study was 300 mg/d of either the free acid form or the sodium salt form of 
phenytoin, with the salt form containing less phenytoin than the free acid 
form. Vma×/F of the tablets and capsules were not significantly different at 
the 95% CI (Table V). 
Because Vma × is the pharmacokinetic parameter that is normally assumed 
to be constant in individual patients, this may suggest hat the difference in 
bioavailabilities (when the differences in dosages caused by differences in the 
salt forms is accounted for) between the tablet and the capsule caused by the 
process of administration (crushing the tablet vs opening the capsule) or the 
dosage forms (IR tablet vs ER capsule) were not important. The number of 
patients who completed the study was small and there was great variability 
among patients even when they were administered the same dosage form. 
Two methods of statistical analysis were used in this study; paired t tests 
and the Wilcoxon signed-rank test. Because the sample size was small and 
there was a patient with outlier values, the data might not have been nor- 
mally distributed, indicating that the Wilcoxon signed-rank test might be 
preferred. 
Limitat ions 
Due to the small cohort observed (17 patients), the actual therapeutic effects 
of the drug might not have been observed, as all of the patients recruited 
were neurosurgical patients who were prescribed phenytoin prophylaxis for 
posttraumatic seizures. This study was performed and observed in a clinical 
setting, making it difficult to control for confounding factors, (eg, conditions of 
admission, abnormal or unstable liver conditions or albumin levels). 
CONCLUSION 
The steady state serum phenytoin concentration was significantly lower with 
ER phenytoin capsules 300 mg/d than IR phenytoin tablets 300 mg/d via naso- 
gastric feeding tube coadministered with a blenderized iet. 
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